Benchmark Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Unicycive Therapeutics (NASDAQ:UNCY – Free Report) had its target price increased by Benchmark to $21.00 in a report issued on Monday, MarketBeat.com reports. The firm currently has a speculative buy rating on the stock. Other equities analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Unicycive Therapeutics from a […]

Leave a Reply

Your email address will not be published.

Previous post Marathon Digital (NASDAQ:MARA) Now Covered by Analysts at Compass Point
Next post Google pledges £5bn UK investment and opens Hertfordshire datacentre amid Trump visit